Minocycline

Generic Name: Minocycline

Brand Names: Amzeeq, Arestin, Dynacin, Minocin, Minolira, Solodyn, Ximino, Zilxi

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₂₇N_₃O_₇

CAS Number: 10118-90-8

Unique Ingredient Identifier: FYY3R43WGO

Background: Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetracyclines.
...

Indication: Oral and topical minocycline are indicated to treat inflammatory lesions of acne vulgaris. Subgingival microspheres are indicated as an adjunct treatment in the reduction of pocket depth in adults with periodontitis. Oral and intravenous formulations are indicated to treat infections of susceptible microorganisms. These include rickettsiae, Mycoplasma pneumo...

Associated Conditions: Bartonellosis, Brucellosis, Campylobacter fetus, Chancroid, Cholera (Disorder), Conjunctivitis, Inclusion, Granuloma Inguinale, Lymphogranuloma Venereum, Nongonococcal urethritis, Periodontitis, Plague, Psittacosis, Q Fever, Relapsing Fever, Respiratory Tract Infections (RTI), Rickettsia Infections, Rickettsialpox, Rocky Mountain Spotted Fever, Trachoma, Tularemia, Typhus infections, Inflammatory lesions

Associated Therapies: -

Clinical Trials

Minocycline as an Adjunctive Therapy for Schizophrenia: a Randomized Controlled Study

Phase 4

Conditions: Schizophrenia

Interventions: Drug: placebo
Drug: Minocycline

First Posted Date: 2010-05-28

Last Posted Date: 2012-01-05

Lead Sponsor: Shalvata Mental Health Center

Target Recruit Count: 50

Registration Number: NCT01133080

Locations: 🇮🇱
Shalvata Mental Health Center, Hod Hasharon, Israel
🇮🇱
shalvata MHC, Hod HAsharon, Israel

A Pilot Study for the Evaluation of Minocycline as a Microglia Inhibitor in the Treatment of Diabetic Macular Edema

Phase 1

Completed

Conditions: Diabetic Macular Edema

Interventions: Drug: Minocycline

First Posted Date: 2010-05-11

Last Posted Date: 2014-10-17

Lead Sponsor: National Eye Institute (NEI)

Target Recruit Count: 6

Registration Number: NCT01120899

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

The Efficacy of Topical Minocycline in Managing Symptomatic Oral Lichen Planus

Phase 3

Conditions: Oral Lichen Planus

Interventions: Drug: Dexamethasone
Drug: Minocycline

First Posted Date: 2010-03-09

Last Posted Date: 2010-03-09

Lead Sponsor: Sheba Medical Center

Target Recruit Count: 30

Registration Number: NCT01083420

Neuroprotection and Repair in Optic Neuritis

Phase 2

Terminated

Conditions: Multiple Sclerosis
Optic Neuritis

Interventions: Drug: Minocycline

First Posted Date: 2010-02-23

Last Posted Date: 2013-01-23

Lead Sponsor: University of Calgary

Target Recruit Count: 6

Registration Number: NCT01073813

A Pilot Study of the Effect of Minocycline on Cerebrospinal Fluid HIV-1 Infection

Completed

Conditions: HIV Infection

Interventions: Drug: Minocycline

First Posted Date: 2010-02-08

Last Posted Date: 2010-02-08

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 7

Registration Number: NCT01064752

Safety and Feasibility of Minocycline in the Treatment of Traumatic Brain Injury (TBI)

Phase 1

Completed

Conditions: Traumatic Brain Injury

Interventions: Drug: Minocycline

First Posted Date: 2010-01-28

Last Posted Date: 2018-09-17

Lead Sponsor: Wayne State University

Target Recruit Count: 15

Registration Number: NCT01058395

Locations: 🇺🇸
Oakwood Southshore Hospital, Trenton, Michigan, United States
🇺🇸
Oakwood Dearborn Hospital, Dearborn, Michigan, United States

Reducing Symptom Burden - Non Small Cell Lung Cancer (NSCLC)

Phase 1

Withdrawn

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Bupropion
Drug: Armodafinil
Drug: Minocycline
Behavioral: Telephone Questionnaire
Drug: Curcumin

First Posted Date: 2010-01-14

Last Posted Date: 2015-03-05

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT01048983

Role of Minocycline in First Episode Psychosis

Phase 1

Completed

Conditions: First Episode Psychosis

Interventions: Drug: Placebo
Drug: Minocycline

First Posted Date: 2009-06-09

Last Posted Date: 2009-06-15

Lead Sponsor: Stanley Medical Research Institute

Target Recruit Count: 52

Registration Number: NCT00916461

Locations: 🇧🇷
Department of Neurology, Psychiatry and Psychological Medicine, University of San Paulo, San Paulo, Brazil
🇵🇰
Civil Hospital Karachi, Karachi, Pakistan
🇵🇰
Karwan e Hayat, Karachi, Pakistan

and more 1 locations

Add-on Pilot Trial of Minocycline to Treat Fragile X Syndrome

Not Applicable

Completed

Conditions: Fragile X Syndrome

Interventions: Drug: Minocycline

First Posted Date: 2009-03-10

Last Posted Date: 2016-02-18

Lead Sponsor: FRAXA Research Foundation

Target Recruit Count: 20

Registration Number: NCT00858689

Locations: 🇨🇦
Surrey Place Centre, Toronto, Ontario, Canada

Minocycline for HIV+ Cognitive Impairment in Uganda

Phase 1

Terminated

Conditions: HIV-associated Cognitive Impairment
HIV Infections

Interventions: Drug: minocycline placebo capsule
Drug: minocycline

First Posted Date: 2009-03-03

Last Posted Date: 2011-02-25

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 73

Registration Number: NCT00855062

Locations: 🇺🇬
Infecious Diseas Institute, Kampala, Uganda

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy